ATRA (Atara Biotherapeutics) Total Assets : $142.7 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Total Assets?

Atara Biotherapeutics's Total Assets for the quarter that ended in Sep. 2024 was $142.7 Mil.

During the past 12 months, Atara Biotherapeutics's average Total Assets Growth Rate was -12.60% per year. During the past 3 years, the average Total Assets Growth Rate was 9.20% per year. During the past 5 years, the average Total Assets Growth Rate was 9.40% per year. During the past 10 years, the average Total Assets Growth Rate was 76.70% per year.

During the past 12 years, Atara Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 278.30%. The lowest was 5.70%. And the median was 116.80%.

Total Assets is connected with ROA %. Atara Biotherapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -67.41%. Total Assets is also linked to Revenue through Asset Turnover. Atara Biotherapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.31.

Atara Biotherapeutics Total Assets Historical Data

The historical data trend for Atara Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Total Assets Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

342.94

588.12

468.13

376.42

165.50

Atara Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															188.79	165.50	165.27	117.28	142.71

Atara Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Atara Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-99.231	+	264.735
	=	165.5

Atara Biotherapeutics's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-90.539	+	233.245
	=	142.7

Atara Biotherapeutics (NAS:ATRA) Total Assets Explanation

Total Assets is connected with ROA %.

Atara Biotherapeutics's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-87.636	/	( (117.284	+	142.706)	/ 2 )
	=	-87.636	/	129.995
	=	-67.41 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Atara Biotherapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	40.19	/	( (117.284	+	142.706)	/ 2 )
=	40.19	/	129.995
=	0.31

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Atara Biotherapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

0HIY:UK

Address

2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Executives

Jill Henrich	officer: EVP, Global Head RA & Quality	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen	officer: EVP, Chief Sci. & Tech Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Eric J Hyllengren	officer: SVP, CFO	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Amar Murugan	officer: SVP, GC & Secretary	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Pascal Touchon	director, officer: President and CEO	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Manher Joshi	officer: EVP, Chief Medical Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard	officer: EVP, Chief Technical Officer	C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont	officer: EVP, Head of R&D	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar	officer: Chief Financial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema	officer: Chief Commercial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell	officer: Chief Tech. Operations Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080